Baseline Pathological Liver Function Tests in Patients With Psoriasis Support the Indication for Systemic Therapy Rather Than Being a Reason Against It: A Real-World Analysis
This study provides real world evidence that systemic therapy with secukinumab, ixekizumab, adalimumab, or apremilast does not present a general risk, but rather an opportunity for patients with psoriasis with elevated LFTs at baseline.
Authors
- Sven Benson (ORCID: https://orcid.org/0000-0002-4487-4258)
- Christopher M. Scheib
- Jan‐Malte Placke (ORCID: https://orcid.org/0000-0002-7842-4669)
- Frederik Krefting (ORCID: https://orcid.org/0000-0002-6164-3726)
- Wiebke Sondermann (ORCID: https://orcid.org/0000-0002-3684-3523)
- Heiner H. Wedemeyer (ORCID: https://orcid.org/0000-0003-2906-0480)
- Stefanie Hölsken (ORCID: https://orcid.org/0000-0001-6756-6963)
Institutions
- Medizinische Hochschule Hannover (DE)
- University of Duisburg-Essen (DE)
Publication Details
- Journal
- Psoriasis Targets and Therapy
- Published
- 2025-02-28
- DOI
- https://doi.org/10.2147/ptt.s502296
- Citations
- 3
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 4.06